Do you have the rights to use CRISPR-based tools?
With more than 1200 patent families with claims including CRISPR, do you actually know whether you are infringing on third-party rights when using this technology?
Four industry experts provide meaningful insights and feedback in this webinar on the following topics:
- Use of CRISPR for model generation (Amélie Rezza, genOway)
- Overview of CRISPR patent landscape (Mathieu Fontaine, Questel)
- Coverage of specific Merck CRISPR-enabling process (Ajay Rastogi, Merck)
- Freedom to use CRISPR/Cas9-based tools (Sandrine Carteau, genOway)